Access cutting-edge triple-negative breast cancer treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access triple-negative breast cancer specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related triple-negative breast cancer treatment provided free
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this triple-negative breast cancer clinical trial in Los Angeles, CA
If you're searching for triple-negative breast cancer treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced triple-negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.